Clinical and pharmacological rationale for principles of therapy for bacterial vaginosis
| Autor: | N.B. Lazareva, E. V. Shikh, A.Yu. Ryazanova, E V Rebrova |
|---|---|
| Rok vydání: | 2021 |
| Předmět: | |
| Zdroj: | Voprosy ginekologii, akušerstva i perinatologii. 20:134-145 |
| ISSN: | 2414-9152 1726-1678 |
| DOI: | 10.20953/1726-1678-2021-3-134-145 |
| Popis: | Metronidazole and clindamycin have been the main medications for the treatment of bacterial vaginosis (BV) for 60 years. Despite the available arsenal of therapeutic agents, the frequency of disease recurrence remains high, and therefore the search for new therapeutic approaches remains relevant. In 2017, the FDA (Food and Drug Administration, USA) approved the use of secnidazole for the treatment of BV. As a member of the 5-nitroimidazole group, secnidazole differs structurally from metronidazole and tinidazole by radical groups attached to the annular nitrogen next to the nitro group. Structural differences may explain physicochemical and biochemical differences (e.g., tissue distribution, metabolic pathways) between these agents within the same pharmacological class of 5-nitroimidazoles. Secnidazole has the longest half-life compared to other medications in this group, which can significantly increase adherence to treatment, due to the possibility of achieving a clinical effect after a single use and a low incidence of adverse drug reactions, comparable to placebo. Key words: bacterial vaginosis, gardnerella vaginalis, lactobacilli, metronidazole, secnidazole |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|